drugset / Trial / NCT00228267

Propofol Injection for Daily Headache

NCT00228267

Phase 2 Completed 28 enrolled University of Alberta
RandomizedParallel-groupDouble-blindTreatment

Summary

Hypothesis A single subanesthetic dose of propofol will result in improved pain and quality of life for the next 30 days in persons with chronic daily headache (CDH) Specific objectives To measure the effect of a single infusion of propofol at 40 mcg / kg / minute over 60 mins on headache-related quality of life (measured by the Headache Disability Index) and on headache severity (measured by the Headache Index) in subjects with chronic daily headache over 30 days45-47

Timeline

Start
2004-09
Primary completion
Completion
2007-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Propofol Small molecule 2.4 mg/kg Intravenous

Indications